October 25, 2015 | Bio-medical company MannKind announced that the Tel Aviv Stock Exchange (TASE) has approved the new listing of it’s common shares. The American company, which develops treatments for diabetes, already trades on the New York Stock Exchange. Hakan Edstrom, President and CEO of MannKind, said that the dual listing will allow his company to diversify its shareholder base.
Related posts
Israeli AI Safety Tool Among TIME’S Best Inventions For 2024
October 31, 2024
TAU Team Discovers Mechanism To Eliminate Cancerous Tumors
October 30, 2024
Ashdod Port Investing In Startups As Part Of Innovation Strategy
October 29, 2024
BGU Develops Fast Fact Checking Via News Sources Not People
October 28, 2024
Facebook comments